Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. (2021)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjno-2020-000096

PubMed Identifier: 34079936

Publication URI: http://europepmc.org/abstract/MED/34079936

Type: Journal Article/Review

Volume: 3

Parent Publication: BMJ neurology open

Issue: 1

ISSN: 2632-6140